Last reviewed · How we verify
Effentora®
A selective kappa opioid receptor antagonist.
A selective kappa opioid receptor antagonist. Used for Treatment of opioid-induced constipation.
At a glance
| Generic name | Effentora® |
|---|---|
| Sponsor | Cephalon |
| Drug class | Opioid receptor antagonist |
| Target | Kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Effentora is a mu-opioid receptor antagonist, but it has a higher affinity for kappa opioid receptors, which may contribute to its therapeutic effects.
Approved indications
- Treatment of opioid-induced constipation
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients (PHASE2)
- Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |